Search

Background Erenumab was approved in Europe for migraine prevention in patients with ≥4 monthly migraine days (MMD). In Spain, Novartis started a personalized managed access program which allowed free access to erenumab before official reimbursement. The Headache Study Group of the Spanish Neurological Society started a registry to monitor real-world safety and efficacy, and all Spanish headache experts were invited to participate. Methods Patients fulfilled ICHD3 criteria for migraine and had ≥ 4MMD. Sociodemographic and clinical data were registered as well as MMD, headache frequency (MHD), prior and concomitant preventive treatment, medication overuse headache (MOH), migraine evolution, adverse events, and PROs: HIT6, MIDAS, and PGIC. A >50% reduction of MMD after 3 months was considered as response. Results We included 210 patients (female 86.7%, mean age 46.4 years old) from 22 hospitals from February 2019 – to – June 2020. Most patients (89.5%) suffered from chronic migraine with a mean evolution of 8.6 years. MOH was present in 70% of patients, and 17.1% had migraine with aura. Average of prior preventive treatment failure was >7 (BoNT/A had been used by 95.2%). Most patients (67,6%) started with erenumab 70mg. 61% of patients were also taking oral preventive drugs or getting simultaneous BoNT/A (27.6%). Responder rate was 37.1% and the mean reduction of MMD was -6.28 and MHD: -8.6. Regarding PROs: MIDAS: -35 p., HIT6: -11.6 p., PIGC: 4.7 p. Predictors of good response were: HIT6 score ( p =0.01), prior preventive treatment failures ( p =0.026), absence of MOH ( p =0.039), and simultaneous BoNT/A treatment ( p

Encephalitis associated with antibodies against the N-methyl-D-aspartate receptor (i.e., anti-NMDAR encephalitis) is an immune-mediated disorder mainly affecting girls and young women with ovarian teratoma. The clinical picture of the disease progresses from headaches and seizures, psychopathological symptoms (i.e., anxiety, psychosis, or hyperreligiosity), and neuropsychological deficits (i.e., memory, attention, and language disintegration) into a state of agitation, catatonia, dysautonomia (i.e., abnormal movements due to inappropriate muscular activity) and facial dyskinesia. Reports of the neuropsychological profile and evolution, as well as the neuropsychological rehabilitation in anti-NMDAR encephalitis in the literature are scarce. We present the case of a 21-year-old woman diagnosed with anti-NMDAR encephalitis and we describe the different neuropsychological evaluation tests performed before and after neuropsychological rehabilitation during the acute period. A profile of fronto-subcortical neuropsychological damage was observed, with executive functions and emotional regulation affected.